Have you been diagnosed with cancer and either your cancer did not respond to treatment or your cancer progressed? If so, you may be able to take part in a research study evaluating the safety of an investigational treatment called LOXO-435 in cancer patients.

The purpose of this study is to test whether the combination treatment of ONC201 and Atezolizumab is safe for the treatment of endometrial cancer.

Have you been diagnosed with colon cancer? If so, you may be able to take part in a research study looking to find out what kind of chemotherapy to recommend to patients based on the presence or absence of circulating tumor DNA (ctDNA) after surgery for colon cancer and if this approach is better or worse than the usual approach for your colon cancer.

The purpose of this study is to learn more about how an investigational drug (tarlatamab) works in people with extensive-stage small cell lung cancer. In this study, we want to learn more about its safety and tolerability (effects good or bad) when used in combination with one of two other drugs (atezolizumab or durvalumab). We also want to learn more about the combination of the study drug with either atezolizumab or durvalumab and carboplatin and etopopside.

Have you been diagnosed with HER2 positive (HER2+) breast cancer and have recently or plan to undergo surgery? If so, you may be able to take part in a research study looking at the safety of giving two drugs trastuzumab and pertuzumab in combination with hormonal therapy after surgery for your breast cancer.

Are you an elderly patient with locally advanced Head and Neck squamous cell carcinoma who is ineligible for standard treatment involving platinum based therapy (e.g. Carboplatin or Cisplatin)? If so, you may be eligible to participate in a clinical research study involving an investigational drug, called NBTXR3.

If you or your child had or currently have abnormal cell growth or a related condition, including brain and nervous system tumors, you may be able to take part in a research study. This is a study for patients who are receiving treatment at UNC hospitals. In this study, we will collect samples to better understand the causes of your disease.

The purpose of this study is to determine if MIRV plus Bev can help to prevent your cancer from returning or delaying your cancer's return.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.